Standard

Statement of policy intent: relaunch of the Innovative Licensing and Access Pathway

A unique initiative which aims to accelerate the time to patient care for transformative medicines and medicine-device combinations.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 6 November 2024

Documents

Statement of policy intent: relaunch of the Innovative Licensing and Access Pathway

HTML

Details

The Innovative Licensing and Access Pathway (ILAP) aims to get the most transformative new medicines to patients in the National Health Service (NHS) more quickly.

It is the only end-to-end access pathway where the developer can work collaboratively with the UK’s national health system, the regulator, and health technology assessment bodies from the early stages of clinical development.

Published 6 November 2024